• Explore /
  • Poster
  • / A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs.

A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs.

Abstract Poster

Authors

null

Jie Li

Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

Jie Li , Jianming Xu , Lin Shen , Chunmei Bai , Zhiwei Zhou , Zhiping Li , Yihebali Chi , Xianjun Yu , Enxiao LI , Nong Xu , Tianshu Liu , Wenhui Lou , Yuxian Bai , Xianglin Yuan , Xiuwen Wang , Ying Yuan , Jia Chen , Tao Zhang , Dianrong Xiu , Weiguo Su

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT02589821; NCT02588170

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4126)

DOI

10.1200/JCO.2022.40.16_suppl.4126

Abstract #

4126

Poster Bd #

112

Abstract Disclosures

Similar Posters

Poster

2021 ASCO Annual Meeting

Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs).

Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs).

First Author: Andrew Scott Paulson

First Author: Arvind Dasari

First Author: Chunmei Bai

First Author: David M. O'Malley